- Home
- AEMD vs ONVO Comparison
AEMD vs ONVO Comparison
Compare AEMD & ONVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEMD
- ONVO
- Stock Information
- Founded
- AEMD 1984
- ONVO 2007
- Country
- AEMD United States
- ONVO United States
- Employees
- AEMD N/A
- ONVO N/A
- Industry
- AEMD Medical/Dental Instruments
- ONVO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AEMD Health Care
- ONVO Health Care
- Exchange
- AEMD Nasdaq
- ONVO Nasdaq
- Market Cap
- AEMD 5.0M
- ONVO 5.3M
- IPO Year
- AEMD N/A
- ONVO N/A
- Fundamental
- Price
- AEMD $0.71
- ONVO $0.33
- Analyst Decision
- AEMD Strong Buy
- ONVO
- Analyst Count
- AEMD 1
- ONVO 0
- Target Price
- AEMD $7.00
- ONVO N/A
- AVG Volume (30 Days)
- AEMD 1.3M
- ONVO 163.1K
- Earning Date
- AEMD 02-12-2025
- ONVO 02-10-2025
- Dividend Yield
- AEMD N/A
- ONVO N/A
- EPS Growth
- AEMD N/A
- ONVO N/A
- EPS
- AEMD N/A
- ONVO N/A
- Revenue
- AEMD N/A
- ONVO $103,000.00
- Revenue This Year
- AEMD N/A
- ONVO $59.08
- Revenue Next Year
- AEMD N/A
- ONVO $18.24
- P/E Ratio
- AEMD N/A
- ONVO N/A
- Revenue Growth
- AEMD N/A
- ONVO N/A
- 52 Week Low
- AEMD $0.24
- ONVO $0.32
- 52 Week High
- AEMD $1.85
- ONVO $1.74
- Technical
- Relative Strength Index (RSI)
- AEMD 51.85
- ONVO 41.39
- Support Level
- AEMD $0.62
- ONVO $0.33
- Resistance Level
- AEMD $0.78
- ONVO $0.37
- Average True Range (ATR)
- AEMD 0.06
- ONVO 0.02
- MACD
- AEMD -0.01
- ONVO -0.00
- Stochastic Oscillator
- AEMD 34.18
- ONVO 16.67
About AEMD Aethlon Medical Inc.
Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
About ONVO Organovo Holdings Inc.
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.